INMD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

104.64M

+6.94%

0.417

-0.78%

81.77M

+5%

0.340

+9.73%

97.67M

+2.16%

0.439

-6.65%

Estimates Revision

The market is revising Upward the revenue expectations for InMode Ltd. (INMD) for FY2025, with the revenue forecasts being adjusted by 0.29% over the past three months. During the same period, the stock price has changed by -5.40%.

Revenue Estimates for FY2025

Revise Upward

+0.29%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.27%

In Past 3 Month

Stock Price

Go Down

-5.40%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast INMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INMD is 17.67 USD with a low forecast of 16.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

4 Hold

0 Sell

Hold

Current: 0.000

Low

16.00

Averages

17.67

High

21.00

Current: 0.000

Low

16.00

Averages

17.67

High

21.00

Canaccord

Hold

downgrade

$16 -> $15

2025-12-17

Reason

Canaccord

Price Target

$16 -> $15

2025-12-17

downgrade

Hold

Reason

Canaccord lowered the firm's price target on InMode to $15 from $16 and keeps a Hold rating on the shares. The firm said they are bullish on the Med-Tech sector heading into 2026 as they expect investor interest given smid-cap valuations continue to remain depressed, while M&A has picked up and the IPO market has opened in some respects. They also highlight how AI is changing our space, enabling improved patient outcomes, increased procedure volumes, more efficiency at the corporate level, and improved surgical accuracy/reproducibility, which they believe could drive some of the greatest changes in healthcare at a time when the system is capacity constrained and in desperate need of solutions.

UBS

Neutral

downgrade

$16

2025-11-06

Reason

UBS

Price Target

$16

2025-11-06

downgrade

Neutral

Reason

UBS lowered the firm's price target on InMode to $16 from $16.25 and keeps a Neutral rating on the shares.

Barclays

Matt Miksic

Overweight

downgrade

$24 -> $21

2025-07-30

Reason

Barclays

Matt Miksic

Price Target

$24 -> $21

2025-07-30

downgrade

Overweight

Reason

Barclays analyst Matt Miksic lowered the firm's price target on InMode to $21 from $24 and keeps an Overweight rating on the shares. The firm updated the company's estimates to reflect the preliminary Q2 results and updated 2025 outlook.

Needham

Mike Matson

Hold

Reiterates

n/a

2025-04-14

Reason

Needham

Mike Matson

Price Target

n/a

2025-04-14

Reiterates

Hold

Reason

Jefferies

Matthew Taylor

Hold

Maintains

$16 → $15

2025-04-14

Reason

Jefferies

Matthew Taylor

Price Target

$16 → $15

2025-04-14

Maintains

Hold

Reason

Jefferies analyst Matthew Taylor lowered the firm's price target on InMode to $15 from $16 and keeps a Hold rating on the shares after the company preannounced Q1 sales of $77.2M-$77.5M and reaffirmed its FY25 guidance of $395M-$405M. The outlook assumes a step-up in the quarterly run rate, which "could prove challenging in this environment," says the analyst, who lowered estimates to reflect softness in Q1.

Needham

Mike Matson

Hold

Reiterates

n/a

2025-04-09

Reason

Needham

Mike Matson

Price Target

n/a

2025-04-09

Reiterates

Hold

Reason

Valuation Metrics

The current forward P/E ratio for Inmode Ltd (INMD.O) is 9.25, compared to its 5-year average forward P/E of 14.89. For a more detailed relative valuation and DCF analysis to assess Inmode Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

14.89

Current PE

9.25

Overvalued PE

23.45

Undervalued PE

6.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

10.49

Current EV/EBITDA

4.34

Overvalued EV/EBITDA

17.67

Undervalued EV/EBITDA

3.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.73

Current PS

2.49

Overvalued PS

9.07

Undervalued PS

2.39

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

INMD News & Events

Events Timeline

No data

News

9.5

01-08Newsfilter

PinnedInMode Projects Q4 2025 Revenue Between $103.6M and $103.8M

9.5

01-08NASDAQ.COM

InMode (INMD) Projects Q4 Revenue of $103.6M to $103.8M, Up from Last Year

9.5

01-08PRnewswire

InMode to Release Q4 and Full Year 2025 Financial Results on February 10, 2026

People Also Watch

Frequently Asked Questions

What is Inmode Ltd (INMD) stock price today?

The current price of INMD is 14.44 USD — it has increased 1.26 % in the last trading day.

What is Inmode Ltd (INMD)'s business?

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.

What is the price predicton of INMD Stock?

What is Inmode Ltd (INMD)'s revenue for the last quarter?

Inmode Ltd revenue for the last quarter amounts to 93.17M USD, decreased -28.46 % YoY.

What is Inmode Ltd (INMD)'s earnings per share (EPS) for the last quarter?

Inmode Ltd. EPS for the last quarter amounts to 0.34 USD, decreased -47.69 % YoY.

What changes have occurred in the market's expectations for Inmode Ltd (INMD)'s fundamentals?

How many employees does Inmode Ltd (INMD). have?

Inmode Ltd (INMD) has 599 emplpoyees as of January 10 2026.

What is Inmode Ltd (INMD) market cap?

Today INMD has the market capitalization of 912.74M USD.